C
Cristina Oliva
Researcher at Takeda Pharmaceutical Company
Publications - 48
Citations - 8369
Cristina Oliva is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Lapatinib & Breast cancer. The author has an hindex of 23, co-authored 47 publications receiving 7848 citations. Previous affiliations of Cristina Oliva include GlaxoSmithKline & University of Southern California.
Papers
More filters
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
Stephen S. Johnston,John Pippen,Xavier Pivot,Mikhail Lichinitser,Saeed Sadeghi,Véronique Diéras,Henry L. Gomez,Gilles Romieu,Alexey Manikhas,M. John Kennedy,Michael F. Press,J. Maltzman,A. Florance,L. O'Rourke,Cristina Oliva,S. Stein,Mark D. Pegram +16 more
TL;DR: In this paper, the authors evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and HER2, to the aromatase inhibitor letrozole as first-line treatment of hormone receptor-positive metastatic breast cancer.
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
J. Maltzman,Marck Pegram,Saeed Sadeghi,Cristina Oliva,M. John Kennedy,Mikhail Lichinitser,Henry L. Gomez Moreno,S. Stein,L. O'Rourke,Stephen S. Johnston,John Pippen,Alexey Manikhas,Michael F. Press,A. Florance,Gilles Romieu,Véronique Diéras,Xavier Pivot +16 more
TL;DR: It is demonstrated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and clinical benefit rates in patients with MBC that coexpresses HR and HER2.
Journal ArticleDOI
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron,Michelle Casey,Michael F. Press,Deborah Lindquist,Tadeusz Pienkowski,C. Gilles Romieu,Stephen Chan,Agnieszka Jagiełło-Gruszfeld,Bella Kaufman,John Crown,Arlene Chan,Mario Campone,Patrice Viens,Neville Davidson,Veira Gorbounova,Johannes Isaac Raats,Dimosthenis Skarlos,B. Newstat,Debasish F. Roychowdhury,Paolo Paoletti,Cristina Oliva,Stephen D. Rubin,S. Stein,Charles E. Geyer +23 more
TL;DR: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.
Journal ArticleDOI
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nan Lin,Véronique Diéras,Devchand Paul,Dominique Lossignol,Christos Christodoulou,Hans-Joachim Stemmler,Henri Roché,Minetta C. Liu,Richard Greil,Eva Ciruelos,Sibylle Loibl,Stefania Gori,Andrew M Wardley,Denise A. Yardley,Adam Brufsky,Joanne L. Blum,Stephen D. Rubin,Bernie Dharan,Klaudia Steplewski,Denise Zembryki,Cristina Oliva,Debasish F. Roychowdhury,Paolo Paoletti,Eric P. Winer +23 more
TL;DR: This study confirms the modest CNS antitumor activity of lapatinib and adds that further studies of Lapatinib-based regimens for CNS metastases from HER2+ breast cancer are warranted.